PATIENT DEMOGRAPHICS AND BASELINE CLINICAL CHARACTERISTICS IN GASTROESOPHAGEAL REFLUX DISEASE BY VONOPRAZAN TREATMENT DURATION: RESULTS FROM A POST-HOC ANALYSIS OF THE VIEW STUDY
Author(s)
Yinglian Xiao, MD, PhD1, Zhenyu Zhang, MD2, Yiyang Dai, MD, PhD3, Kailun Liang, MD4, Fang Zhou, MD4, Minhu Chen, MD, PhD1.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 3The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China, 4Takeda (China) International Trade Co., Ltd, Shanghai, China.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Nanjing First Hospital, Nanjing Medical University, Nanjing, China, 3The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China, 4Takeda (China) International Trade Co., Ltd, Shanghai, China.
OBJECTIVES: To assess the impact of baseline demographics, patient characteristics and concomitant medications on vonoprazan treatment duration in patients with gastroesophageal reflux disease (GERD).
METHODS: VIEW (NCT04501627) was a multicentre, single-arm, prospective, real-world study in China. Patients received 20 mg vonoprazan orally once daily for 4 weeks (8 weeks for insufficient healing). Pearson’s chi-square (categorial variables) or t-test (continuous variables) was used to compare differences between the 4- and 8-week treatment duration groups. This post-hoc analysis was based on the safety analysis population (patients with GERD who took ≥1 vonoprazan dose in routine care and provided safety information).
RESULTS: Among the 2307 patients with GERD, mean (SD) age and body mass index were 48.9 (13.6) years and 23.9 (3.5) kg/m2, respectively; 60.8% were male and majority (75.4%) had never smoked. Most (77.0%) were treated with vonoprazan for 4 weeks, whereas 23.0% were treated for 8 weeks. The 8-week patients were significantly older (mean [SD]: 50.7 (13.81) years) than 4-week patients (48.4 [13.51] years). For Los Angeles (LA) classification, the proportion of patients with LA class A or B was similar in both groups (4-week: 58.0%; 8-week: 60.0%), whereas LA class C or D was observed more frequently in the 8-week (13.3%) vs 4-week (4.4%) group (p<0.001). At enrolment, more 8‑week patients had hypertension (p<0.001), all-day heartburn or regurgitation and nighttime heartburn/regurgitation (all p<0.001) symptoms, more severe symptoms (p<0.001), greater heartburn (p=0.003) and regurgitation (p=0.016) frequency, and higher baseline GERDQ score (p<0.001). Concomitant medication use for the cardiovascular (p<0.001) and nervous (p=0.006) systems was greater in the 8-week group, whereas use of anti-infectives for systemic use (p=0.016), proton pump inhibitors (p=0.035) and mucosal protective agents (p=0.008) was greater in the 4-week group.
CONCLUSIONS: Patients requiring 8-week vonoprazan treatment for GERD had distinct baseline demographics, clinical characteristics, and concomitant medication profiles vs those with 4-week treatment.
METHODS: VIEW (NCT04501627) was a multicentre, single-arm, prospective, real-world study in China. Patients received 20 mg vonoprazan orally once daily for 4 weeks (8 weeks for insufficient healing). Pearson’s chi-square (categorial variables) or t-test (continuous variables) was used to compare differences between the 4- and 8-week treatment duration groups. This post-hoc analysis was based on the safety analysis population (patients with GERD who took ≥1 vonoprazan dose in routine care and provided safety information).
RESULTS: Among the 2307 patients with GERD, mean (SD) age and body mass index were 48.9 (13.6) years and 23.9 (3.5) kg/m2, respectively; 60.8% were male and majority (75.4%) had never smoked. Most (77.0%) were treated with vonoprazan for 4 weeks, whereas 23.0% were treated for 8 weeks. The 8-week patients were significantly older (mean [SD]: 50.7 (13.81) years) than 4-week patients (48.4 [13.51] years). For Los Angeles (LA) classification, the proportion of patients with LA class A or B was similar in both groups (4-week: 58.0%; 8-week: 60.0%), whereas LA class C or D was observed more frequently in the 8-week (13.3%) vs 4-week (4.4%) group (p<0.001). At enrolment, more 8‑week patients had hypertension (p<0.001), all-day heartburn or regurgitation and nighttime heartburn/regurgitation (all p<0.001) symptoms, more severe symptoms (p<0.001), greater heartburn (p=0.003) and regurgitation (p=0.016) frequency, and higher baseline GERDQ score (p<0.001). Concomitant medication use for the cardiovascular (p<0.001) and nervous (p=0.006) systems was greater in the 8-week group, whereas use of anti-infectives for systemic use (p=0.016), proton pump inhibitors (p=0.035) and mucosal protective agents (p=0.008) was greater in the 4-week group.
CONCLUSIONS: Patients requiring 8-week vonoprazan treatment for GERD had distinct baseline demographics, clinical characteristics, and concomitant medication profiles vs those with 4-week treatment.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO171
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Gastrointestinal Disorders